Gemcitabine: vascular toxicity and prothrombotic potential

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Gemcitabine is associated with significant thrombotic and vascular adverse events.
• Expanding indications for gemcitabine in oncology and hematology necessitate a thorough understanding of these risks.

Purpose of the Study:

• To review the prothrombotic potential and vascular effects of gemcitabine.
• To synthesize data from research, clinical trials, and clinical practice regarding gemcitabine's vascular toxicity.

Main Methods:

• Literature search of PubMed database.
• Review of Food and Drug Administration (FDA) drug information.

Main Results:

• The incidence of thrombotic and vascular toxicity with gemcitabine appears higher than previously estimated.
• Reported toxicities include venous thromboembolism, acute arterial events, digital ischemia, vasculitis, thrombotic microangiopathy, capillary leak syndrome, and posterior leukoencephalopathy syndrome.
• These toxicities may be more frequent when gemcitabine is used in combination with platinum agents.

Conclusions:

• Gemcitabine poses a significant risk of vascular toxicity, including potentially fatal events.
• Caution is advised when prescribing gemcitabine to patients with pre-existing vascular disease, thromboembolic conditions, collagenoses, heart failure, or liver damage.
• Individual patient factors, comorbidities, and the risk:benefit ratio must be carefully considered before initiating gemcitabine therapy.